Salix Pharmaceuticals Ltd., the Raleigh, N.C.-based pharmaceutical company that acquired San Diego-based Santarus Pharmaceuticals in November for $2.6 billion, is reportedly closing Santarus’ operations and laying off up to 200, according to a newspaper report and a notice filed with the state of California Employment Development Department.

“Salix carefully analyzed its available options and with regret decided to close the Santarus facility,” the company reportedly wrote in a Jan. 6 note to employees. “Salix will be discontinuing substantially all of Santarus’ operations in the state of California.”

The layoff date given in the filing is March 6. Salix did not respond to attempts to reach the company for comment.

Salix President and CEO Carolyn Logan said in November that the companies will meld their sales forces. Santarus was a maker of diabetes and gastrointestinal drugs, and Salix has a vast portfolio of gastrointestinal drugs.

SDBJ Staff Report